Stockreport

Onconova Presents Data on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2017 Meeting

Onconova Therapeutics, Inc.  (ONTX) 
Last onconova therapeutics, inc. earnings: 11/12 05:10 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.onconova.com/investor-overview
PDF Oral rigosertib as a single agent demonstrates activity in a Phase 2 trial for lower-risk MDS32% of 62 evaluable patients, and 44% of patients receiving optimal dosing, [Read more]